Introduction
Vini Tablet 10 mg has been used in trials studying the treatment of Erosive Esophagitis.
Uses
Vini Tablet 10 mg is a potassium-competitive acid blocker used in the treatment of erosive diseases of the digestive tract, including reflux esophagitis and duodenal ulcers.
Associated Conditions
Dosage
Gastric ulcer and duodenal ulcer: The usual adult dose for oral use is 20 mg of Vini Tablet 10 mg administered orally once daily an 8-week treatment for gastric ulcer and a 6-week treatment for duodenal ulcer.
Reflux esophagitis: The usual adult dose for oral use is 20 mg of Vini Tablet 10 mg administered once daily for a total of 4 weeks of treatment. If that dosing proves insufficient, the administration should be extended, but for no longer than 8 weeks of treatment.
For the maintenance therapy of reflux esophagitis showing recurrence and recrudescence, the dose for oral use is 10mg of Vini Tablet 10 mg once daily. However, when the efficacy is inadequate, the dosage may be increase up to 20 mg of Vini Tablet 10 mg once daily.
Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration: The usual adult dose is one tablet of 10 mg of Vini Tablet 10 mg administered orally once daily.
Prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID): administration The usual adult dose is one tablet of 10 mg of Vini Tablet 10 mg administered orally once daily.
Adjunct to Helicobacter pylori eradication: For adults, the following three-drug regimen should be administered orally at the same time twice daily for seven days: 20 mg of Vini Tablet 10 mg, 750 mg of amoxicillin hydrate and 200 mg of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg twice daily.
If Helicobacter pylori eradication with a three-drug regimen comprising a proton pump inhibitor, amoxicillin hydrate and clarithromycin has been unsuccessful, as an alternative treatment, adults should be administered the following three drugs orally twice daily for seven days: 20 mg of Vini Tablet 10 mg, 750 mg of amoxicillin hydrate and 250 mg of metronidazole.
Reflux esophagitis: The usual adult dose for oral use is 20 mg of Vini Tablet 10 mg administered once daily for a total of 4 weeks of treatment. If that dosing proves insufficient, the administration should be extended, but for no longer than 8 weeks of treatment.
For the maintenance therapy of reflux esophagitis showing recurrence and recrudescence, the dose for oral use is 10mg of Vini Tablet 10 mg once daily. However, when the efficacy is inadequate, the dosage may be increase up to 20 mg of Vini Tablet 10 mg once daily.
Prevention of recurrence of gastric or duodenal ulcer during low-dose aspirin administration: The usual adult dose is one tablet of 10 mg of Vini Tablet 10 mg administered orally once daily.
Prevention of recurrence of gastric or duodenal ulcer during non-steroidal anti-inflammatory drug (NSAID): administration The usual adult dose is one tablet of 10 mg of Vini Tablet 10 mg administered orally once daily.
Adjunct to Helicobacter pylori eradication: For adults, the following three-drug regimen should be administered orally at the same time twice daily for seven days: 20 mg of Vini Tablet 10 mg, 750 mg of amoxicillin hydrate and 200 mg of clarithromycin. The dose of clarithromycin may be increased as clinically warranted. However, dosage should not exceed 400 mg twice daily.
If Helicobacter pylori eradication with a three-drug regimen comprising a proton pump inhibitor, amoxicillin hydrate and clarithromycin has been unsuccessful, as an alternative treatment, adults should be administered the following three drugs orally twice daily for seven days: 20 mg of Vini Tablet 10 mg, 750 mg of amoxicillin hydrate and 250 mg of metronidazole.
